Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

NCT03785652 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder

Interventions

DRUG: LY03005 extended-release tablets 40 mg
DRUG: LY03005 extended-release tablets 80 mg group
DRUG: LY03005 extended-release tablets 120 mg group
DRUG: LY03005 extended-release tablets 160 mg group
DRUG: Placebo group

Sponsor

Luye Pharma Group Ltd.

Collaborators

[object Object]